Rhabdomyolysis Associated with the Use of Tirzepatide

Area of Science:

• Endocrinology
• Pharmacology
• Neurology

Background:

• Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonist, is increasingly used for weight loss.
• While offering benefits like weight reduction and improved glycemic control, potential serious adverse events require monitoring.

Purpose of the Study:

• To report a case of severe rhabdomyolysis in a patient treated with tirzepatide for weight loss.
• To raise awareness among clinicians about the potential association between GLP-1 agonists and rhabdomyolysis.

Main Methods:

• Case report of a 35-year-old female without comorbidities.
• Clinical presentation, diagnostic workup including muscle biopsy, treatment, and outcome were documented.
• Exclusion of other potential contributing factors to rhabdomyolysis.

Main Results:

• The patient developed severe rhabdomyolysis and necrotizing myopathy requiring hospitalization.
• Rhabdomyolysis resolved after discontinuation of tirzepatide and supportive intravenous fluid management.
• No other cause for rhabdomyolysis was identified.

Conclusions:

• GLP-1 agonists, including tirzepatide, should be considered a potential contributing factor in patients presenting with rhabdomyolysis.
• Clinicians must be aware of rare but serious side effects like rhabdomyolysis associated with tirzepatide.
• Thorough discussion of risks and benefits, alongside close patient monitoring, is crucial when prescribing these medications.